Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 3 (March)

1. Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.
   Mol Cell Neurosci, 28(3): 496-508. [Abstract] [Full-text]
2. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.
   Neurochem Int, 46(5): 409-22. [Abstract] [Full-text]
3. The intimate mediator: a carer's experience of Alzheimer's.
   Scand J Caring Sci, 19(1): 2-11. [Abstract] [Full-text]
4. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach.
   J Neuropsychiatry Clin Neurosci, 17(1): 51-60. [Abstract] [Full-text]
5. Calcium dysregulation, IP3 signaling, and Alzheimer's disease.
   Neuroscientist, 11(2): 110-5. [Abstract] [Full-text]
6. Family-based association between Alzheimer's disease and variants in UBQLN1.
   N Engl J Med, 352(9): 884-94. [Abstract] [Full-text]
7. Discretionary hospitalization of nursing home residents with and without Alzheimer's disease: a multilevel analysis.
   J Aging Health, 17(2): 207-38. [Abstract] [Full-text]
8. Caregiver psychological adjustment and institutionalization of persons with Alzheimer's disease.
   J Aging Health, 17(2): 172-89. [Abstract] [Full-text]
9. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.
   Neuron, 45(5): 675-88. [Abstract] [Full-text]
10. Homing in on intracellular Abeta?
    Neuron, 45(5): 639-42. [Abstract] [Full-text]
11. Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu.
    Neurobiol Aging, 26(7): 1023-8. [Abstract] [Full-text]
12. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.
    Neurobiol Aging, 26(7): 1015-22. [Abstract] [Full-text]
13. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer's disease.
    Neurobiol Aging, 26(7): 1011-4. [Abstract] [Full-text]
14. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease.
    Neurobiol Aging, 26(7): 1005-10. [Abstract] [Full-text]
15. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models.
    Neurobiol Aging, 26(7): 995-1000. [Abstract] [Full-text]
16. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease.
    Ann Neurol, 57(3): 429-34. [Abstract] [Full-text]
17. Vascular endothelial growth factor gene variability is associated with increased risk for AD.
    Ann Neurol, 57(3): 373-80. [Abstract] [Full-text]
18. Depressive symptoms, sex, and risk for Alzheimer's disease.
    Ann Neurol, 57(3): 381-7. [Abstract] [Full-text]
19. Abnormal cortical functional connections in Alzheimer's disease: analysis of inter- and intra-hemispheric EEG coherence.
    J Zhejiang Univ Sci B, 6(4): 259-64. [Abstract] [Full-text]
20. Oxidative damage and Alzheimer's disease: are antioxidant therapies useful?
    Drug News Perspect, 18(1): 13-9. [Abstract] [Full-text]
21. Vitamin E in neurodegenerative disorders: Alzheimer's disease.
    Ann N Y Acad Sci, 1031: 249-62. [Abstract] [Full-text]
22. Patterns of brain activation in patients with mild Alzheimer's disease during performance of subtraction: an fMRI study.
    Clin Imaging, 29(2): 94-7. [Abstract] [Full-text]
23. Factors relating to the use of physical restraints in psychogeriatric care: a paradigm for elder abuse.
    Z Gerontol Geriatr, 38(1): 10-8. [Abstract] [Full-text]
24. Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia.
    Neurobiol Dis, 18(3): 638-48. [Abstract] [Full-text]
25. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
    Neurobiol Dis, 18(3): 602-17. [Abstract] [Full-text]
26. Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease.
    Neurobiol Dis, 18(3): 450-8. [Abstract] [Full-text]
27. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination.
    Vaccine, 23(17): 2327-30. [Abstract] [Full-text]
28. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice.
    Proc Natl Acad Sci U S A, 102(10): 3811-6. [Abstract] [Full-text]
29. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease.
    Arch Phys Med Rehabil, 86(3): 576-81. [Abstract] [Full-text]
30. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.
    Health Aff (Millwood), 24(2): 483-90. [Abstract] [Full-text]
31. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease.
    J Neurol Sci, 229: 285-92. [Abstract] [Full-text]
32. The regulation of beta-secretase by cholesterol and statins in Alzheimer's disease.
    J Neurol Sci, 229: 269-73. [Abstract] [Full-text]
33. Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.
    J Neurol Sci, 229: 211-3. [Abstract] [Full-text]
34. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    J Neurol Sci, 229: 141-6. [Abstract] [Full-text]
35. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia.
    J Neurol Sci, 229: 75-9. [Abstract] [Full-text]
36. The acoustic cortex in vascular dementia: a Golgi and electron microscope study.
    J Neurol Sci, 229: 51-5. [Abstract] [Full-text]
37. Survival following dementia onset: Alzheimer's disease and vascular dementia.
    J Neurol Sci, 229: 43-9. [Abstract] [Full-text]
38. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease.
    J Neurol Sci, 229: 37-41. [Abstract] [Full-text]
39. Emerging prospects for the disease-modifying treatment of Alzheimer's disease.
    Biochem Pharmacol, 69(7): 1001-8. [Abstract] [Full-text]
40. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients.
    Exp Gerontol, 40(3): 165-71. [Abstract] [Full-text]
41. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
    Arch Neurol, 62(3): 454-9. [Abstract] [Full-text]
42. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu.
    Arch Neurol, 62(3): 447-53. [Abstract] [Full-text]
43. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease.
    Arch Neurol, 62(3): 425-30. [Abstract] [Full-text]
44. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.
    J Cell Biol, 168(6): 863-8. [Abstract] [Full-text]
45. Semantic feature knowledge and picture naming in dementia of Alzheimer's type: a new approach.
    Brain Lang, 93(1): 79-94. [Abstract] [Full-text]
46. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice.
    Cell, 120(5): 701-13. [Abstract] [Full-text]
47. Exercise your amyloid.
    Cell, 120(5): 572-4. [Abstract] [Full-text]
48. Context processing and context maintenance in healthy aging and early stage dementia of the Alzheimer's type.
    Psychol Aging, 20(1): 33-46. [Abstract] [Full-text]
49. Metacognition and false recognition in Alzheimer's disease: further exploration of the distinctiveness heuristic.
    Neuropsychology, 19(2): 253-8. [Abstract] [Full-text]
50. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.
    J Neurochem, 93(1): 105-17. [Abstract] [Full-text]
51. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases.
    J Biol Chem, 280(12): 11648-55. [Abstract] [Full-text]
52. The heterogeneity of picture-supported narratives in Alzheimer's disease.
    Brain Lang, 93(2): 173-84. [Abstract] [Full-text]
53. Preserved synaptic vesicle recycling in hippocampal neurons in a mouse Alzheimer's disease model.
    Biochem Biophys Res Commun, 330(1): 34-8. [Abstract] [Full-text]
54. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
    Maturitas, 50(4): 312-20. [Abstract] [Full-text]
55. Alzheimer disease is substantially preventable in the United States -- review of risk factors, therapy, and the prospects for an expert software system.
    Med Hypotheses, 64(5): 960-7. [Abstract] [Full-text]
56. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease.
    Neuroscience, 132(1): 123-35. [Abstract] [Full-text]
57. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease.
    Neuroscience, 132(1): 73-86. [Abstract] [Full-text]
58. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
    J Neural Transm, 112(4): 519-37. [Abstract] [Full-text]
59. Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease.
    Int J Geriatr Psychiatry, 20(3): 238-46. [Abstract] [Full-text]
60. Relationship of exercise and other risk factors to depression of Alzheimer's disease: the LASER-AD study.
    Int J Geriatr Psychiatry, 20(3): 261-8. [Abstract] [Full-text]
61. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory.
    Brain, 128: 773-87. [Abstract] [Full-text]
62. Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease.
    Am J Med Genet B Neuropsychiatr Genet, 134(1): 1-5. [Abstract] [Full-text]
63. Alzheimer's disease with and without cerebral infarcts.
    J Neurol Sci, 231(1): 3-11. [Abstract] [Full-text]
64. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease.
    J Neurosci Res, 80(1): 120-8. [Abstract] [Full-text]
65. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide.
    Biophys J, 88(4): 2706-13. [Abstract] [Full-text]
66. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development.
    J Neurosci Res, 80(2): 151-9. [Abstract] [Full-text]
67. Mitochondrial aging and dysfunction in Alzheimer's disease.
    Prog Neuropsychopharmacol Biol Psychiatry, 29(3): 407-10. [Abstract] [Full-text]
68. Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation.
    Biochemistry, 44(13): 4977-83. [Abstract] [Full-text]
69. Identification of hippocampus-related candidate genes for Alzheimer's disease.
    Ann Neurol, 57(4): 585-8. [Abstract] [Full-text]
70. Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia.
    Dement Geriatr Cogn Disord, 19(4): 204-12. [Abstract] [Full-text]
71. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    Dement Geriatr Cogn Disord, 19(4): 189-95. [Abstract] [Full-text]
72. Diminished production of proinflammatory cytokines in patients with Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(4): 184-8. [Abstract] [Full-text]
73. Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(4): 171-83. [Abstract] [Full-text]
74. Automated neuropsychological assessment metrics (ANAM) measures of cognitive effects of Alzheimer's disease.
    Arch Clin Neuropsychol, 20(3): 403-8. [Abstract] [Full-text]
75. Methods to improve the detection of mild cognitive impairment.
    Proc Natl Acad Sci U S A, 102(13): 4919-24. [Abstract] [Full-text]
76. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
    Am J Psychiatry, 162(4): 676-82. [Abstract] [Full-text]
77. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
    Am J Psychiatry, 162(4): 667-75. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.